Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
12.81
0.00 (0.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
790.02M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 84.28M |
| MeiraGTx Holdings | 81.39M |
| Kura Oncology | 67.48M |
| Arbutus Biopharma | 14.08M |
| Crescent Biopharma | 10.84M |
| Absci | 2.80M |
| Allogene Therapeutics | 22.00K |
DSGN News
- 8 hours ago - Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates - GlobeNewsWire
- 7 weeks ago - Design Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 2 months ago - Design Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Design Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Design Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference - Transcripts
- 5 months ago - Design Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference - Transcripts
- 6 months ago - Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results - GlobeNewsWire